• The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need 
  • The FDA confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New Drug (IND) application in acute MS relapses, planned for submission in the fourth quarter of 2026
  • Privosegtor, a novel neuroprotective candidate, continues to advance across core neuro-ophthalmology indications, including optic neuropathies and acute MS relapses, and is transforming Oculis as an emerging leader in neuro-ophthalmology
  • Oculis will host a virtual R&D Day in the fourth quarter of 2026 to provide further updates on its clinical pipeline